Literature DB >> 36156120

Investigating the psychometric properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, CHU-9D, and PedsQL in children and adolescents with osteogenesis imperfecta.

Richard Huan Xu1,2, Liling Zhu2, Rongjia Sun3, Rachel Lee-Yin Tan4, Nan Luo4, Sainan Zou5, Dong Dong6.   

Abstract

The objective of this study was to evaluate and compare the psychometric properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, CHU-9D, and PedsQL, in a sample of children and adolescents with osteogenesis imperfecta (OI). A web-based cross-sectional survey was conducted among Chinese children and adolescents with OI in 2021. The EQ-5D-Y-3L, EQ-5D-Y-5L, CHU-9D, and PedsQL were used to assess the health-related quality of life for the participants. Construct validity, including convergent and divergent validity, known-group validity, and test-retest reliability, was examined to assess the psychometric properties of the measures. A total of 157 pediatric OI patients self-completed the questionnaire. Few of them reported the full health status. A strong ceiling effect was observed for all dimensions on the EQ-5D-Y and most on CHU-9D. Most dimensions of the EQ-5D-Y and CHU-9D showed statistically significant correlations with the hypothesized PedsQL subscales. The test-retest reliability for the EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU-9D was acceptable. The EQ-5D-Y-5L showed a better known-group validity than EQ-5D-Y-3L, CHU-9D, and PedsQL in differentiating patients in risk groups.
CONCLUSION: The results confirmed that the EQ-5D-Y and CHU-9D are reliable and valid in pediatric OI patients. The EQ-5D-Y-5L performed better than EQ-5D-Y-3L regarding acceptability, convergent validity, and discriminatory power. WHAT IS KNOWN: • Performance of the preference-based measures has never been reported in patients with Osteogenesis imperfecta. WHAT IS NEW: • The EQ-5D-Y demonstrated higher sensitivity and discriminatory power than the CHU-9D in patients with osteogenesis Imperfecta • The EQ-5D-Y-3L performed slightly better than EQ-5D-Y-5L regarding convergent validity and discriminant ability.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  CHU-9D; EQ-5D-Y; Health-related quality of life; Osteogenesis Imperfecta; PedsQL; Psychometric properties

Year:  2022        PMID: 36156120     DOI: 10.1007/s00431-022-04626-1

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.860


  8 in total

1.  Measuring health-related quality of life with the EQ-5D-Y instrument in children and adolescents with asthma.

Authors:  Sofi Bergfors; Mimmi Åström; Kristina Burström; Ann-Charlotte Egmar
Journal:  Acta Paediatr       Date:  2015-02       Impact factor: 2.299

Review 2.  Method agreement analysis: a review of correct methodology.

Authors:  P F Watson; A Petrie
Journal:  Theriogenology       Date:  2010-06       Impact factor: 2.740

Review 3.  Recessively inherited forms of osteogenesis imperfecta.

Authors:  Peter H Byers; Shawna M Pyott
Journal:  Annu Rev Genet       Date:  2012       Impact factor: 16.830

4.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

Review 5.  Genetic causes and mechanisms of Osteogenesis Imperfecta.

Authors:  Joohyun Lim; Ingo Grafe; Stefanie Alexander; Brendan Lee
Journal:  Bone       Date:  2017-02-15       Impact factor: 4.398

Review 6.  Quality of life in osteogenesis imperfecta: A mixed-methods systematic review.

Authors:  N Dahan-Oliel; S Oliel; A Tsimicalis; K Montpetit; F Rauch; M J Dogba
Journal:  Am J Med Genet A       Date:  2015-09-14       Impact factor: 2.802

7.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).

Authors:  M Herdman; C Gudex; A Lloyd; Mf Janssen; P Kind; D Parkin; G Bonsel; X Badia
Journal:  Qual Life Res       Date:  2011-04-09       Impact factor: 4.147

8.  EQ-5D-Y-5L: developing a revised EQ-5D-Y with increased response categories.

Authors:  Simone Kreimeier; Mimmi Åström; Kristina Burström; Ann-Charlotte Egmar; Narcis Gusi; Michael Herdman; Paul Kind; Miguel A Perez-Sousa; Wolfgang Greiner
Journal:  Qual Life Res       Date:  2019-02-09       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.